Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics.
The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | -4.58 Decreased by -5.63 K% | - |
| Nov 6, 25 | -1.49 Increased by +90.24% | - |
| Jul 30, 25 | -5.65 Decreased by -3.54 K% | - |
| Jun 18, 25 | -18.39 Decreased by -10.72 K% | -3.64 Decreased by -405.22% |
| Feb 27, 25 | -0.08 Increased by +42.86% | -0.09 Increased by +11.11% |
| Nov 29, 24 | -15.24 Decreased by -10.78 K% | -0.11 Decreased by -13.75 K% |
| Aug 1, 24 | -0.15 Decreased by -19.23% | -0.16 Increased by +3.13% |
| May 10, 24 | -0.17 Increased by 0.00% | -0.17 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 10.84 M Increased by +N/A% | -92.40 M Decreased by -1.18 K% | Decreased by -852.06% Decreased by N/A% |
| Sep 30, 25 | 30.56 M Increased by +N/A% | -24.61 M Decreased by -150.47% | Decreased by -80.51% - |
| Jun 30, 25 | 0.00 Decreased by N/A% | -21.79 M Decreased by -115.84% | Decreased by N/A% - |
| Mar 31, 25 | N/A Decreased by N/A% | -2.34 M Increased by +78.17% | - - |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -7.22 M Increased by +20.44% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | N/A Decreased by N/A% | -9.82 M Decreased by -6.76% | - - |
| Jun 30, 24 | N/A Decreased by N/A% | -10.10 M Decreased by -22.24% | - - |
| Mar 31, 24 | N/A Decreased by N/A% | -10.74 M Decreased by -3.64% | - - |